Company / Revenue
BioNexus Gene Lab Corp Revenue History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$7.4M
FY2025
5-year range
$7.4M / $13.4M
FY2021-FY2025
Trend
-21.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has declined for 4 consecutive years, from $13M in FY2021 to $7M in FY2025.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of -8.2%.
Declined from $10M to $7M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -12.1%
- 5-Year CAGR
- -8.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- BioNexus Gene Lab Corp's revenue has declined for 4 consecutive years.
- 5-year CAGR of -8.2%, indicating a declining trend.
- In FY2025, revenue decreased 21.9% year-over-year.
- Peak revenue was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.4M | -21.9% |
| FY2024 | $9.5M | -2.7% |
| FY2023 | $9.8M | -10.6% |
| FY2022 | $10.9M | -18.2% |
| FY2021 | $13.4M | +17.3% |
| FY2020 | $11.4M | +8872.0% |
| FY2019 | $127.0K | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026